Cyclosporine

MENLO PARK, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that data on two of its proprietary glaucoma and dry eye technologies, the OMNI® Surgical System and the TearCare® System , will be presented at this year’s ASCRS Annual Meeting held in Washington, DC. “We look forward to highlighting new clinical data on our interventional technologies at the 2026 ASCRS meeting, the largest annual meeting for anterior segment surgeons,” said Paul Badawi, CEO and co-founder of Sight Sciences. “The data reinforce the durability and versatility of OMNI by demonstrating significant reductions in long-term diurnal IOP fluctuations regardless of lens status, while new TearCare results underscore the strength of our technology and showcase its clinical benefit to demonstrate early and sustained superiority of TearCare over Restasis in achieving a clinically relevant change in tear film stability. Collectively, the strength and growing depth of our clinical portfolio supports broader eyecare provider adoption and differentiated positioning in our core markets. We are thankful to all our clinical collaborators for their work demonstrating and sharing the benefits of our interventional technologies.” TearCare System Oral and Poster Presentations: Outcomes for Localized Heat Therapy (LHT) or Cyclosporine in Dry Eye Disease (DED) Signs and Symptoms by Baseline Severity, Saturday, April 11 at 3:45 PM ET, at the Walter E. Washington Convention Center – Level 2, 209B. Presenting author: Mina Farahani, MD Clinically Relevant Change in Tear Break-up Time (TBUT) with Localized Heat Therapy or Cyclosporine in Dry Eye Disease (DED) – poster presentation. Lead author: Yuna Rapoport, MD OMNI Surgical System Poster Presentation: Longer-term Diurnal IOP (DIOP) Fluctuations Following Canaloplasty and Trabeculotomy (CT) with and without cataract surgery – poster presentation. Lead author: Mark Pyfer, MD About Sight Sciences Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System and OMNI® Edge Surgical System are implant-free, minimally invasive glaucoma surgery technologies indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit for more information. Sight Sciences and TearCare are trademarks of Sight Sciences registered in the United States. OMNI, SION, SmartLids, and the Sight Sciences logo are trademarks of Sight Sciences registered in the United States, European Union and other territories. All educational content of the ASCRS Annual Meeting is planned by its program committee, and ASCRS does not endorse, promote, approve, or recommend the use of any products, devices, or services. © 2026 Sight Sciences. All rights reserved. Forward-Looking Statements This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with such safe harbor provisions. Any statements made in this press release or during the earnings call that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include, but are not limited to, statements concerning anticipated data presentation on our glaucoma and dry eye technologies, and beliefs regarding broader adoption of our technologies. These statements often include words such as "anticipate," "expect," “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our business, results of operations and financial condition and could cause actual results to differ materially from those expressed in the forward-looking statements. These statements are not guarantees of future performance or results. These forward-looking statements are subject to and involve numerous risks, uncertainties and assumptions, including those discussed under the caption “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, as may be updated from time to time in subsequent filings, and you should not place undue reliance on these statements. These cautionary statements are made only as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Investor contact: Philip Taylor Gilmartin Group 415.937.5406 Investor.Relations@Sightsciences.com Media contact: pr@SightSciences.com

德大医械有若干技术讨论群，欢迎医械行业同仁进群，与大家交流技术及工作问题。来源：坐标-趣撩星举例如下： 排除标准条目 核心目的 科学逻辑 随机前10周内使用过生物制剂者或未超过5个半衰期（以较长时间为准） 彻底消除既往生物制剂的残留药理效应，避免干扰MG-K10的疗效与安全性评估 生物制剂（如抗IL-4R、抗IgE等）半衰期长，体内残留时间久，未充分洗脱会持续抑制IL-4/IL-13通路，人为改善AD症状，无法判断本研究药物（单抗类）的真实疗效；5个半衰期后体内药物浓度仅余约3%，10周为保守安全窗，确保无残留效应影响试验结果。 随机前4周内使用过靶向抑制剂（如JAK抑制剂等）、系统糖皮质激素、环孢素及其他免疫抑制剂（如甲氨蝶呤、霉酚酸酯[MMF]及硫唑嘌呤等）、磷酸二酯酶（PDE4）抑制剂、紫外线治疗、针对AD的系统性中药治疗 排除强效免疫/抗炎治疗的短期干扰，保证受试者基线疾病活动度真实可靠 此类治疗可快速、显著减轻AD炎症反应，造成“假性改善”，导致基线评分失真、疗效被高估；同时系统免疫抑制剂会掩盖感染风险、影响实验室指标，干扰安全性评估；4周洗脱期可使药物基本清除，让疾病恢复自然基线状态。 随机前1周内接受过外用糖皮质激素、外用钙调磷酸酶抑制剂、抗生素复方乳膏、外用中药治疗等局部治疗AD的药物 避免局部治疗药物影响皮损评分（EASI/IGA/BSA），确保疗效评估准确 外用药物直接作用于AD皮损，1周内即可明显改善红斑、瘙痒、浸润等症状，若未洗脱，会导致基线皮损评分偏低，治疗后疗效被高估，造成试验结果失真；1周洗脱期可使局部药物效应基本消失。 随机前6个月接受过变应原特异性免疫治疗（脱敏治疗） 排除脱敏治疗对AD长期病程及过敏体质的持续影响，避免混淆疗效来源 脱敏治疗起效缓慢但效应持续时间长（可达数月），会持续下调Th2型免疫反应、减轻AD严重程度；6个月洗脱期可使前期脱敏效应充分衰减，避免其与MG-K10的疗效叠加或混淆，确保疗效归因于试验药。 随机前3个月内或计划在研究期间接种活疫苗/减毒活疫苗 降低活疫苗在免疫调节状态下的播散性感染风险，保障受试者安全 本研究药物（单抗类）作为IL-4R抑制剂，会轻度抑制机体免疫功能，可能降低对活疫苗的控制能力，导致活疫苗在体内异常复制引发感染；3个月是疫苗诱导免疫反应及潜在病毒复制风险的安全窗口期，可有效规避感染风险。 随机前3个月或者5个半衰期（以时间较长者为准）参加了其他药物临床研究，或计划在研究期间参加其它药物临床研究 避免既往试验药物残留效应及多重药物暴露，确保试验环境纯净 其他在研药物的药理作用、代谢特点及与本研究药物（单抗类）的相互作用均不明确，残留药物可能干扰本研究药物（单抗类）的疗效与安全性评估；3个月或5个半衰期取较长者，是国际通用的洗脱规则，可彻底避免交叉干扰。 既往使用过白细胞介素4受体α亚基（IL-4Rα）单克隆抗体药物，经研究者判断，发生耐药或与药物相关严重AE的受试者 排除对同类靶点无效或高风险人群，保证试验人群同质性，降低安全风险 对IL-4Rα单抗已发生耐药者，本研究药物（单抗类）大概率同样无效，会拉低试验整体有效率，影响试验统计结果；曾发生相关严重AE者，再次暴露于同靶点药物时，安全风险显著升高，不符合伦理与试验安全性原则。 既往参加过本研究药物的临床试验 避免重复暴露导致的数据污染，保证受试者独立性与试验数据可靠性 既往暴露于本研究药物（单抗类）可能产生残留药效、抗药抗体（ADA），干扰本次试验的疗效与安全性解读；同时同一受试者重复参与试验会破坏随机设计与统计假设，导致数据失真，不符合临床试验规范。 随机前4周内接受系统性（口服及静脉）抗细菌、病毒、真菌治疗者；当前有任何症状、体征或实验室检查异常提示可能存在急性或者亚急性感染者（如发热、咳嗽、尿急、尿痛、腹痛、腹泻、皮肤感染性伤口等） 排除活动性感染，避免干扰疗效评估、降低受试者安全风险，确保安全性数据纯净 本研究药物（单抗类）会轻度抑制机体免疫功能，可能加重潜在感染或掩盖感染症状，增加受试者安全风险；同时急性/亚急性感染本身会导致炎症指标升高、皮肤异常，干扰AD疗效评分（如EASI/IGA），无法准确判断本研究药物（单抗类）的真实疗效；4周窗口期可确保既往抗感染治疗结束、感染完全控制，避免残留感染的干扰。返回搜狐，查看更多